Dogwood Therapeutics, Inc. (DWTX) Form 8-K — Oct 19, 2026
$DWTXForm 8-KItems 1.01, 3.02, 8.01, 9.01Filed Oct 19, 2026, 8:45 AM ET0001104659-26-116748Original filing
Dogwood Therapeutics signed a Subscription Agreement to sell 4,098,360 shares at $1.22 per share to Sealbond Limited, a subsidiary of its largest shareholder CK Life Sciences, raising approximately $5 million gross in a private placement expected to close by October 29, 2026. Proceeds are earmarked for Phase 3 preparatory activities for Halneuron® and working capital, extending the company's cash runway through March 31, 2027. The placement is priced at-the-market under Nasdaq rules with no warrants included.
Key figures
- Gross Proceeds
- 5000000
- Offering Price
- 1.22
- Shares Offered
- 4098360
- Trial Sites
- 25
- Runway Through
- March 31, 2027
- Closing Deadline
- October 29, 2026
- Phase2b Patients
- 239
- Purchase Price Total
- $4,999,999.20
- Liquidated Damages Cap
- 5.0% of aggregate purchase price
- Sealbond Ownership Pre Deal
- 63.9%
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.